Fast, accurate diagnoses when and where they’re needed most
Danaher’s Diagnostics companies are innovating to solve complex health challenges for patients around the world, enabling healthcare providers to diagnose diseases with unprecedented speed and precision.
New solutions in cancer and hematology
Research on hematology and oncology is thriving, generating new insights into how best to identify and treat subtypes of disease with cutting-edge therapies. At Danaher, our businesses touch every step of the cancer patient journey, from initial diagnosis to follow-up in remission.
Preparing for the “silver tsunami”
The worldwide burden of neurodegenerative disease is growing, but so are solutions to combat it. With new therapies for Alzheimer’s finally available, we are working to enable physicians to diagnose the disease and other neurodegenerative conditions – the first step toward treating them.
Enabling rapid and responsible diagnosis
Patients are often treated with antibiotics without confirming an infection is present or what type of infection it is. Danaher is developing new diagnostics that rapidly identify pathogens and the host response they induce to guide appropriate antibiotic use and lower the potential for antimicrobial resistance.
Robust and rapid acute care
In life-or-death situations, precision matters – and so does speed. We are pioneering new ways to characterize critical illness in real time throughout the patient’s stay in the hospital: from the emergency department, through the intensive care unit, operating room or general hospital floor.
Matching therapeutics to patients
With new treatment modalities, such as antibody-drug conjugates in cancer, come new needs for identifying the patients most likely to benefit from the right therapies at the right times. We’re developing technologies that can stratify patient populations based on meaningful measurements.
Keeping recurrence at bay
The better we can monitor patients for indications of disease recurrence, the earlier we can intervene – and the more precise we can make their treatment.
Innovation strategy at Danaher
Collaborative action on a global scale
We take a multi-pronged approach to translating research insights into real impact – one that leverages synergies between our technologies and our operating companies to improve diagnostic capabilities around the world. And we work with a sense of urgency and responsibility to patients, who don’t have time to wait.
Breadth and sensitivity of technologies
Our diverse technologies are pushing the barriers of quality of data collection and analytical sensitivity, allowing us to observe, quantify and track biomarkers like never before so we can better understand and treat disease.
Combining data modalities
We pursue and combine multiple testing modalities (genomic, proteomic, and tissue-based), prioritize reproducibility, and responsibly leverage bioinformatics and AI to allow for the creation of complex, multi-analyte assays.
Credibility and footprint
With industry-leading technologies already in use in laboratories around the world, our innovations can be implemented almost immediately for faster solutions on trusted systems.
Enabling digital collaboration
Generative and predictive AI, data integration, and knowledge generation are revolutionizing healthcare – and diagnostics are no exception. We’re leveraging current capabilities and building new ones to put digital tech to work for healthcare providers and patients.
Driving adoption through collaboration
Inventing new technologies isn’t enough. We also work with key partners in the innovation ecosystem to overcome barriers to adoption, from manufacturing bottlenecks to challenges in regulation and reimbursement.
Innovation by the numbers
Danaher Summit
Our 2023 Danaher Summit: Insights to Impact convened diagnostics leaders, patients, healthcare professionals and innovators to share their insights, research findings, and practical experiences in this critical field.
Innovation in the news
To treat Alzheimer’s, first we must diagnose it
Julie Sawyer Montgomery, Vice President and Group Executive, Danaher Diagnostics Platform, shares her perspective on the critical role that accessible diagnostics will play in treating Alzheimer’s disease.
The future of pathology is digital
Rob Monroe, Vice President and Chief Scientific Officer of Oncology, Danaher Diagnostics Platform, illuminates how cutting-edge technology and AI-driven tools are transforming the art and science of disease diagnosis
Danaher Announces Two New Centers of Innovation in Diagnostics
Two new labs aim to transform precision medicine by accelerating the development of companion diagnostics and complementary diagnostics.
Our Diagnostics companies
Beckman Coulter
Beckman Coulter develops, manufactures and markets innovative products to simplify and automate complex biomedical testing.
Cepheid
Cepheid is dedicated to improving healthcare by developing, manufacturing and marketing accurate yet easy-to-use molecular systems and tests.
HemoCue
HemoCue is a global leader in a field of diagnostics known as near-patient, or point‐of‐care, testing.
Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions.
Mammotome
Mammotome is the global leader in breast biopsy markers, offering clinicians customized solutions for every breast biopsy need.
Radiometer
Every day almost one million blood samples are tested around the world using Radiometer equipment – ten samples a second, 600 samples a minute and 40,000 samples an hour.